Company Name: Regenxbio Inc.

Regenxbio Inc. is a biotech company engaged in developing and licensing recombinant adeno-associated virus (AAV) gene therapy. Using its NAV Technology Platform, the company develops in vivo gene therapy products designed to treat various diseases, including homozygous familial hypercholesterolemia (HoFH), Mucopolysaccharidosis Type I (MPS I) and wet age-related macular degeneration (wet AMD).

Ticker Symbol: RGNX (NASDAQ)

Company Website: www.regenxbio.com

Social Media: Regenxbio LinkedIn

Headquarters: Rockville, MD